GALDERMA
11.6.2022 00:00:08 CEST | Business Wire | Press release
Galderma announced today at the Vegas Cosmetic Surgery & Aesthetic Dermatology meeting, topline results from two phase III clinical studies (NCT04249583, NCT04249687) demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, improves both glabellar and lateral canthal lines with a rapid onset of action and a long duration up to six months.1,2
Developed by Galderma, RelabotulinumtoxinA is a highly-active, innovative, complex-free, and ready-to-use liquid botulinum toxin A with a proprietary strain and manufactured using a state-of-the-art, unique process.1,3 RelabotulinumtoxinA is designed as a liquid, avoiding the traditional requirement to reconstitute from powder, eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. The READY (RE labotulinumtoxin A esthetic D evelopment StudY) phase III clinical program is composed of four phase III clinical trials which enrolled more than 1,900 participants.
"We developed this innovative neuromodulator to respond directly to the needs of healthcare professionals and the expectations of patients who are looking for a safe, effective, long-lasting treatment that offers consistency in results for frown lines and crow’s feet, which can have a significant impact on patients’ self-esteem and well-being. We are looking forward to submitting the data to U.S. and global authorities as part of the next step in bringing this potential, new treatment to patients.”
Baldo Scassellati Sforzolini, M.D.
Global Head of Research & Development
Galderma
Both studies met their primary endpoint, demonstrating a significant ≥2-grade composite improvement (as assessed by both subject and investigator) in glabellar line severity and lateral canthal line severity vs. placebo at Month 1, with rapid onset of action and up to six-month duration of action.
The first clinical study, READY-1 , was a multicenter, randomized, double-blind, placebo-controlled, phase III trial of RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines (frown lines) in 300 participants followed for six months.1 Results from READY-1 showed that RelabotulinumtoxinA significantly reduced glabellar line severity and was well tolerated.1
READY-1 met its primary endpoint for participants with moderate-to-severe glabellar lines – the response to RelabotulinumtoxinA was significantly higher than placebo after one month (82.9% vs. 0%; P<0.001).1
In the trial, RelabotulinumtoxinA had a rapid onset of effect (median 2 days, 39% of participants reported an effect on Day 1) and the effects were long-lasting, persisting for up to six months. The median time to return to baseline severity was >24 weeks (end of study).1
Participant satisfaction with treatment was high for RelabotulinumtoxinA vs. placebo. At Month 1, 97% of participants were satisfied with the outcome of treatment and 86% remained satisfied at Month 6.1 Treated participants were also highly satisfied with how natural they looked (97% at Month 1, 88% at Month 6).1
The second study, READY-2 , was a multicenter randomized,double-blind, placebo-controlled, phase III trial of RelabotulinumtoxinA for the treatment of moderate-to-severe lateral canthal lines (crow’s feet).2 Results from the six-month study, involving 303 participants, showed that treatment with RelabotulinumtoxinA improved lateral canthal lines, with high participant satisfaction and a rapid onset of effect.2
READY-2 met its primary endpoint with the response among those participants receiving treatment significantly higher than placebo (51.8% vs. 1.4%, P<0.001).2
The onset of effect was rapid (median 2 days, 34% of participants reported onset of effect by Day 1) and the effect was long-lasting, up to six months. The median time to return to baseline severity was 173 days (24.7 weeks).2
Safety and tolerability profile
In both studies, RelabotulinumtoxinA was well tolerated.1,2
All treatment-related adverse events
were mild-to-moderate, non-serious and transient.1,2
In READY-1, 3.6% of treated participants (0%, placebo) experienced a treatment-related adverse event; the most common was headache.1 In READY-2, treatment-related adverse events occurred in 6.1% of treated participants (5.5%, placebo) and the most common was injection-site bruising.2
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that spans the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
References:
1. Shridharani, S., et al . Treatment of moderate-to-severe glabellar lines with RelabotulinumtoxinA, a new liquid botulinum toxin: Clinical efficacy and safety results from the READY-1 Phase III trial. Poster presented at Vegas Cosmetic Surgery & Aesthetic Dermatology 2022, Las Vegas, NV, June 8-11, 2022
2. Ibrahim, SF, et al . Treatment of lateral canthal lines with RelabotulinumtoxinA, a new liquid botulinum toxin: Clinical efficacy and safety results from the READY-2 Phase III trial. Poster presented at Vegas Cosmetic Surgery & Aesthetic Dermatology 2022, Las Vegas, NV, June 8-11, 2022.
3. Liljegren Sundberg, Å and Ståhl, U. Relabotulinum toxin – a novel, high purity BoNT-A1 in liquid formulation. Poster presented at TOXINS, virtual online event, January 16-17, 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Expands Relationship With Anthropic With Verified Claude Connector for Global Messaging17.11.2026 10:00:00 CET | Press release
New integration enables Claude users to send and track messages across SMS, RCS, MMS and Viber through Infobip. Global AI-first cloud communications platform Infobip has expanded its collaboration with Anthropic with the launch of the Infobip Message connector in the Claude Marketplace. The Anthropic-verified connector enables developers, enterprises and builders using Claude to add global messaging capabilities to AI agents without building separate integrations for individual communication channels. The integration connects Claude with Infobip’s global communications infrastructure, enabling AI agents to send messages across SMS, RCS, MMS and Viber through a single connector. Using Infobip’s send and check status tools, agents can trigger outbound messages and track their delivery status, allowing them to incorporate real-world communication into automated workflows. For businesses building agentic AI applications, the connector can support use cases such as order confirmations, deli
Luminor Partners With Plumery to Accelerate Delivery of Digital Banking Solutions17.11.2026 09:55:00 CET | Press release
Luminor has partnered with financial technology company Plumery, using its headless digital platform to accelerate the delivery of selected digital banking solutions across Estonia, Latvia and Lithuania. Plumery was selected because its technology and approach align well with Luminor’s strategy. The cooperation forms part of Luminor’s broader work to modernise its technology, simplify its products and strengthen its digital channels. Under the partnership, Luminor uses Plumery’s headless, API-first architecture to design and deliver digital banking experiences in combination with the bank’s own applications, customer journeys and integrations. This allows Luminor to develop and introduce new functionality more efficiently, while retaining control over how its digital services are designed and integrated. Luminor Bloom, hosted on Luminor’s new cloud-based banking platform, is the first solution delivered through the partnership. Plumery provides the digital banking interface used for Lu
Oasis Networks Selects PacketLight for Burstable Wavelength Services17.11.2026 09:35:00 CET | Press release
PacketLight Networks, a provider of DWDM and OTN optical transport solutions, today announced that Oasis Networks has selected its 800G transport and OLS optical amplification platforms to support the development of burstable wavelength services in Portugal. PacketLight’s open transport architecture supports Oasis’ plans to allocate optical capacity through software as customer requirements change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117351242/en/ PacketLight’s 800G DWDM transport and OLS optical amplification support Oasis Networks’ Lisbon–Sines connection and the development of burstable wavelength services. The connection between Lisbon and Sines is now in place, with the Sines endpoint at Start Campus. A proof of concept on Oasis’ operational network demonstrated software-controlled optical path establishment and reconfiguration. PacketLight has also completed the design for future site interconnects around
Abu Dhabi International Boat Show Opens This Week With World Premieres and Record Participation17.11.2026 09:27:00 CET | Press release
Held under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region, the Abu Dhabi International Boat Show (ADIBS) returns from 19 to 22 November 2026 at ADNEC Marina Hall for its eighth and largest edition yet, bringing together 1,210 exhibitors and brands from 57 countries, a 13% increase on 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116669938/en/ ADNEC Marina Hall - ADNEC Group, Abu Dhabi – United Arab Emirates (Photo: AETOSWire) Organised by ADNEC Group under the theme “Life on and Beyond the Water”, the show spans more than 96,000 square metres and will feature 168 boats on display in the marina. Additionally, luxury yachts, houseboats, leisure boats and marine sports equipment will be launched for the first time in the region. “This year’s edition is set to be the largest in the Show’s history, with strong growth across key performance indicators reflectin
Lakestar and Rochefort Asset Management Co-Lead Series A for Tiberius Aerospace at over $1 Billion Valuation17.11.2026 09:00:00 CET | Press release
Financing will accelerate production of long-range precision munitions and expand allied sovereign manufacturing capacity. Lakestar, a European technology investment firm and Rochefort Asset Management (Rochefort), a U.S. national security-focused investment firm licensed under the U.S. Department of War's Office of Strategic Capital (OSC) and the Small Business Administration (SBA), today jointly announced that they have co-led an $85 million Series A financing round for defense technology company Tiberius Aerospace, Inc. (Tiberius). The investment values Tiberius at more than $1 billion on a post-money basis making it the latest defense technology unicorn. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117903633/en/ Tiberius Aerospace becomes a defense tech unicorn The round attracted new investors including Dream Ventures and Aero X Ventures, alongside other institutional investors, with participation from existing inv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
